Five-year c linical o utcomes after p ercutaneous e dge-to-edge m itral v alve r epair: Insights from the m ulticenter GRASP-IT r egistry

Marianna Adamo, Carmelo Grasso, Davide Capodanno, Antonio Popolo Rubbio, Salvatore Scandura, Cristina Giannini, Francesca Fiorelli, Claudia Fiorina, Luca Branca, Nedy Brambilla, Francesco Bedogni, Anna Sonia Petronio, Salvatore Curello, Corrado Tamburino

Research output: Contribution to journalArticlepeer-review


Limited evidence is available on 5 -year clinical outcomes after percutaneous edge-to-edge mitral valve repair. Methods: The Getting Reduction of mitrAl inSufficiency by Percutaneous clip implantation in ITaly (GRASP-IT ) is a multicenter registry including 304 consecutive patients undergoing Mitraclip between October 2008 and October 2013 at 4 Italian centers. Primary end point (all-cause mortality) and secondary end point (all-cause mortality or heart failure [ HF ] hospitalization) were evaluated up to 5 year s and between 1 and 5 year s. Results: Cumulative incidence of the primary and secondary end points at 1, 2, 3, 4, and 5 years were 15.1%, 26.4%, 35.5%, 42.1%, and 47.3% and 29.1%, 41.7%, 49.8%, 56%, and 62.3%, respectively. Landmark analysis between 1 and 5 years showed an incidence of primary and secondary end point of 37.9% and 46.8%, respectively. Five-year event rates were significantly higher in patients with functional isch emic mitral regurgitation ( MR ) compared to other etiologies. MR recurrence and left ventricular ejection fraction <30% were associated with an increased risk of both primary and secondary end point s. EuroSCORE II >5% was associated with an increased risk of 5-year mortality. Isch emic etiology of MR, baseline serum creatinine >1.5 mg/ dL, chronic obstructive pulmonary disease, and previous HF hospitalizations were independent predictors of 5-year secondary end point. Conclusions: At 5-year follow-up after Mitraclip, nearly half of patients died and almost two third s died or were admitted for HF. MR recurrence, isch emic etiology, high comorbidity burden (i e, EuroSCORE II >5%, chronic obstructive pulmonary disease ), and advanced cardiomyopathy (i e, left ventricular ejection fraction <30%, prior HF admission, creatinine >1.5 mg/dL) significantly increase the relative risk of 5-year clinical events.

Original languageEnglish
Pages (from-to)32-41
Number of pages10
JournalAmerican Heart Journal
Publication statusPublished - Nov 2019

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Five-year c linical o utcomes after p ercutaneous e dge-to-edge m itral v alve r epair: Insights from the m ulticenter GRASP-IT r egistry'. Together they form a unique fingerprint.

Cite this